GLP-1s and Opioids: The GI Risk Clinicians May Be Missing

GLP-1 receptor agonists have transformed the treatment of type 2 diabetes, but their effects on gastrointestinal motility remain an important clinical consideration. Opioids can also slow gastrointestinal function, raising an obvious question: what happens when patients need both? New research examining GLP-1 and opioid interactions suggests that opioid choice may matter, particularly when clinicians consider short-term risks of severe constipation and bowel obstruction.

Table of Contents

• Why GLP-1s and opioids deserve closer attention
• What the latest study found
• Why oxycodone may carry greater GI risk
• Clinical implications for monitoring patients
• Conclusion
• Frequently asked questions

Why GLP-1 and Opioid Use Raises GI Concerns

Gastrointestinal effects are familiar to clinicians prescribing GLP-1 receptor agonists such as semaglutide, dulaglutide, and liraglutide. Nausea, vomiting, diarrhea, and constipation can occur, while delayed gastric emptying is an established pharmacologic effect of the drug class.

The FDA has noted that GLP-1 activity can reduce intestinal motility. GLP-1 receptors are found throughout the gastrointestinal tract and in neural pathways involved in regulating motility. In addition, FDA reviews have discussed postmarketing reports of ileus with GLP-1 receptor agonists.

Opioids create another layer of concern. These medications can inhibit gastrointestinal motility, contributing to constipation and, in some patients, more serious bowel complications.

Therefore, concurrent GLP-1 and opioid use deserves attention because both therapies can affect GI function, although through different mechanisms. Until recently, however, clinicians had limited large-scale evidence showing whether the risk differed according to the opioid prescribed.

That evidence is beginning to emerge.

New Study Finds GI Risk Varies by Opioid

A September 2026 study published in Diabetes Care examined short-term gastrointestinal outcomes among adults with type 2 diabetes receiving GLP-1 receptor agonists who subsequently started an opioid.

Researchers conducted a population-based new-user cohort study using U.S. insurance claims from 2016 through 2025. The analysis included 411,188 adults with type 2 diabetes receiving GLP-1 therapy who initiated oxycodone, hydrocodone, or tramadol.

Among these patients, 24.4% started oxycodone, 48.5% hydrocodone, and 27.1% tramadol. The investigators evaluated a composite outcome consisting of severe constipation, bowel obstruction, and gastroparesis.

The differences were notable.

During the 30-day follow-up period, the weighted absolute risk of a motility-related GI event was 0.51% with oxycodone. In comparison, the risk was 0.35% with hydrocodone and 0.33% with tramadol.

Oxycodone was associated with a 48% higher relative risk compared with hydrocodone and a 55% higher relative risk compared with tramadol. Meanwhile, hydrocodone and tramadol had similar risks.

Importantly, the higher risk associated with oxycodone appeared to be driven by severe constipation and bowel obstruction. Researchers did not identify a difference in gastroparesis risk among the three opioid groups.

What Concurrent GLP-1 and Opioid Use May Mean

These findings should not be interpreted as evidence that patients receiving GLP-1 therapy cannot use oxycodone. Nor does an observational study establish that oxycodone directly caused the additional events.

However, the results provide a useful signal for clinicians.

The absolute event rates remained below 1% during the 30-day period. Nevertheless, severe constipation and bowel obstruction can have important consequences, especially in patients who already have GI symptoms or other risk factors.

Additional 2026 research reinforces the need for attention. A separate propensity-matched analysis presented in Diabetes compared GLP-1 receptor agonist users with and without concurrent opioid exposure. Concurrent therapy was associated with higher rates of gastroparesis diagnoses, GI symptoms, gastric emptying studies, and antiemetic use.

Together, these studies suggest that GI risks associated with concurrent GLP-1 and opioid use deserve consideration during medication review. Still, they do not prove that every patient receiving both drug classes faces a clinically significant problem.

Think Beyond the GLP-1 Prescription

Medication reconciliation becomes especially important when a patient reports new constipation, persistent nausea, abdominal distension, or other changes after starting an opioid.

Clinicians should consider the entire medication list rather than automatically attributing symptoms to the GLP-1 agent. Opioid dose, duration, indication, other constipating medications, hydration status, and underlying gastrointestinal disease may all influence symptoms.

Likewise, timing matters. A patient who recently increased a GLP-1 dose and then begins opioid therapy may require closer observation than someone who has tolerated a stable GLP-1 regimen for months.

Monitoring Patients Who Need Both Therapies

The new findings do not establish a universal prescribing hierarchy among oxycodone, hydrocodone, and tramadol. Pain management decisions involve numerous factors, including pain severity, renal and hepatic function, contraindications, drug interactions, and the risks associated with opioid therapy itself.

However, GI risk can become another consideration in individualized prescribing.

Before initiating an opioid in someone taking a GLP-1 receptor agonist, clinicians can document baseline bowel habits and ask about existing nausea, vomiting, abdominal pain, bloating, or constipation. A history of gastroparesis or bowel obstruction may also warrant particular attention.

Patient counseling is equally important. Patients should understand that worsening constipation is not always a minor inconvenience. Persistent vomiting, severe or increasing abdominal pain, significant abdominal distension, inability to pass stool or gas, or other concerning symptoms require prompt medical evaluation.

Furthermore, clinicians should reassess symptoms after opioid initiation rather than waiting until the next routine diabetes visit. This may be especially useful during the first several weeks, since the Diabetes Care analysis specifically identified differences within 30 days.

For patients needing individualized medical guidance, referral to an appropriate clinician or Healthcare.pro can help connect them with professional care.

Conclusion

The latest evidence adds an important dimension to GLP-1 safety discussions. Among more than 411,000 adults with type 2 diabetes receiving GLP-1 receptor agonists, oxycodone initiation was associated with a higher short-term risk of motility-related GI events than hydrocodone or tramadol.

The absolute risks were small, and observational findings cannot establish causality. Even so, the potential GI effects of combining GLP-1 therapy with opioids deserve greater attention when clinicians select medications, review gastrointestinal symptoms, and counsel patients.

Ultimately, the message is not to avoid necessary opioid therapy. Instead, clinicians should recognize overlapping effects on gastrointestinal function and monitor patients accordingly.

Frequently Asked Questions

Can GLP-1 receptor agonists and opioids be used together?

They can be prescribed concurrently when clinically appropriate. However, because both drug classes can affect gastrointestinal function, patients may require additional monitoring for constipation and other GI symptoms.

Which opioid showed the highest GI risk in the new study?

Oxycodone was associated with the highest 30-day risk. Motility-related GI events occurred in 0.51% of oxycodone initiators compared with 0.35% for hydrocodone and 0.33% for tramadol.

Can taking a GLP-1 drug with an opioid increase gastroparesis risk?

The new Diabetes Care study did not find meaningful differences in gastroparesis risk among patients initiating oxycodone, hydrocodone, or tramadol. However, other observational research has associated concurrent GLP-1 and opioid exposure with increased GI symptom burden.

Should clinicians avoid oxycodone in patients taking GLP-1 drugs?

The study does not support a blanket recommendation to avoid oxycodone. Instead, its findings suggest GI risk should be one consideration alongside pain-management needs, patient characteristics, contraindications, and other medication-related risks.

What symptoms warrant closer attention?

Severe or worsening constipation, persistent vomiting, increasing abdominal pain, marked abdominal distension, or inability to pass stool or gas can warrant prompt medical assessment, particularly when symptoms are new or worsening.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.